Rapid multiple indication assessments
Rapid assessment of multiple ophthalmology orphan/non-orphan indications across the EU5 and the US

This project utilised the Lightning Insights platform
EU5 and US
Therapy Area:
Japanese pharmaceutical company
The Challenge
The client had been presented with a portfolio opportunity for a new advanced therapeutic medicinal product (ATMP) in ophthalmology​

With relatively little experience in ATMP reimbursement but a strong background in ophthalmology, the team required support to understand the value of each indication and the access implications when faced with difficult reimbursement challenges​
Project objectives
To guide the client team through the clinical and commercial value associated with each indication, including an understanding of:​

•Clinical landscape ​

•Unmet need ​

•Competitive landscape ​

•Pricing and reimbursement considerations for ATMP therapies, including a deep knowledge of prior ATMP HTA submissions and associated price agreements/innovative access schemes

•The pricing, access and uptake opportunity with each indication​
The team researched the landscape for all ATMP launches in Europe to provide a baseline understanding of the environment​

A number of TPPs were created for each indication utilising desk research to understand the clinical and competitive environment​

TPPs were tested with an expert stakeholder panel of clinicians and payers to rank their relative attributes and produce an understanding of how they addressed the market, benchmarked against pricing potential​

This was synthesised into a final report bringing together all project modules​
The report was structured to present the relevant merits of each indication and how the target asset could potentially address the market, valuing each indication individually so that key decisions could be made easily​

This allowed direct input into the already established internal decision-making process for prioritising investments into new indications